Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday

Castle Biosciences (CSTL) is scheduled to release its Q3 2025 earnings on November 3rd, 2025, with analysts forecasting an EPS of ($0.35) on $71.06 million in revenue. This follows the company's strong Q2 2025 performance, where it significantly surpassed expectations by reporting $0.15 EPS against a ($0.51) consensus and $86.18 million in revenue. The stock, currently trading around $25.50, maintains a 'Moderate Buy' consensus rating with an average price target of $36.57, and institutional investors hold a substantial 92.60% stake, reflecting notable professional interest despite varied recent analyst actions.

Analysis

Castle Biosciences (CSTL) significantly outperformed Q2 2025 consensus estimates, reporting an EPS of $0.15 against a ($0.51) forecast and revenue of $86.18 million, surpassing the $71.53 million expectation. This strong beat contrasts with upcoming Q3 2025 analyst expectations for an EPS of ($0.35) and revenue of $71.0620 million, suggesting a potential sequential revenue decline. The company maintains a positive return on equity of 2.37% despite a negative net margin of 2.73%.

The stock currently trades at $25.50, above its 50-day ($23.14) and 200-day ($20.08) moving averages, indicating recent positive momentum. Institutional investors hold a substantial 92.60% of the stock, with several firms significantly increasing their stakes, reflecting strong professional interest. Analyst sentiment is predominantly positive, with a "Moderate Buy" consensus rating and an average price target of $36.57, despite some mixed individual ratings.

CSTL exhibits robust liquidity with a quick ratio of 6.69 and a current ratio of 6.85, alongside a very low debt-to-equity ratio of 0.02. While analysts project negative EPS for both the current ($0) and next fiscal year ($-2), the company's strong balance sheet and recent earnings beat provide a foundation. Its focus on molecular diagnostics for dermatologic cancers and Barrett's esophagus underpins long-term potential.

Key Decisions for Investors

• Investors should closely monitor the upcoming Q3 2025 earnings report on November 3rd to assess if the company can sustain its Q2 outperformance against lower analyst expectations.
• Evaluate the company's long-term growth prospects in molecular diagnostics, considering its strong balance sheet and product pipeline in dermatologic cancers and Barrett's esophagus.
• Assess the current stock valuation of $25.50 against the "Moderate Buy" consensus and average price target of $36.57, while acknowledging the negative P/E ratio and projected negative EPS.